H.C. Wainwright analyst Robert Burns raised the firm’s price target on Nurix Therapeutics (NRIX) to $35 from $30 and keeps a Buy rating on the shares. The firm says NX-5948’s response rate continues to increase in the most recent dataset.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics initiated with a Buy at BTIG
- Nurix Therapeutics Reports Promising Trial Results for NX-5948
- Nurix Therapeutics holds a pharmaceutical update conference call
- Nurix Therapeutics initiated with an Outperform at BMO Capital
- Nurix Therapeutics announces PRIME designation for NX-5948 from EMA